Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Autor:	Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi‐Long Wu
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	advanced NSCLC exon 20 insertion human epidermal growth factor receptor 2 immune checkpoint inhibitor non‐exon 20 insertion Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Molecular Oncology, Vol 17, Iss 8, Pp 1581-1594 (2023)
Druh dokumentu:	article
ISSN:	1878-0261 1574-7891
DOI:	10.1002/1878-0261.13439
Popis:	The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to compare clinical/molecular features and immune checkpoint inhibitor (ICI)‐based therapy efficacy between patients with ex20ins and non‐ex20ins. Two external cohorts (TCGA, n = 21; META‐ICI, n = 30) were used for validation. In the GLCI cohort, 68.2% of patients displayed programmed death‐ligand 1 (PD‐L1) expression
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/d5aadd22e14b45079cd59c661d0f474c Zobrazit plný text záznamu Plný text View record in DOAJ